Home > Boards > US Listed > Biotechs > DermTech Inc (DMTK)

8K New Private placement...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
TallTrader Member Profile
Member Level 
Followed By 38
Posts 693
Boards Moderated 5
Alias Born 05/12/01
160x600 placeholder
DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Lar... Business Wire - 1/14/2021 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/13/2021 4:22:13 PM
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cuta... Business Wire - 1/12/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/11/2021 6:05:37 PM
DermTech Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purchase Additiona... Business Wire - 1/11/2021 4:01:00 PM
DermTech Announces Pricing of Public Offering of Common Stock Business Wire - 1/7/2021
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 4:11:03 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/6/2021 4:07:36 PM
DermTech Announces Proposed Public Offering of Common Stock Business Wire - 1/6/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:26:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/5/2021 4:37:54 PM
DermTech Announces Appointment of General Counsel Business Wire - 1/5/2021 4:30:00 PM
DermTech Receives Positive Medical Coverage by Geisinger Health System Business Wire - 12/29/2020 5:05:00 PM
DermTech Management to Present at the ICR Conference 2021 Business Wire - 12/28/2020 4:01:00 PM
DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% &... Business Wire - 12/17/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:40:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:37:46 PM
DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Gr... Business Wire - 12/11/2020 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2020 6:05:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:11:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:08:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:07:34 PM
DermTech Enters Into Agreement With Blue Shield of California Business Wire - 12/10/2020 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/9/2020 4:44:40 PM
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit Business Wire - 12/3/2020 4:30:00 PM
TallTrader Member Level  Monday, 03/02/20 12:24:10 PM
Re: None
Post # of 95 
8K New Private placement...

Item 1.01 Entry into a Material Definitive Agreement.

On February 28, 2020, DermTech, Inc., or the Company, entered into a securities purchase agreement, or the Purchase Agreement, with certain institutional investors, or the Investors, for a private placement of the Company’s equity securities, or the Private Placement. Cowen and Company, LLC served as lead placement agent for the Private Placement, with William Blair & Company, L.L.C. acting as joint placement agent. Lake Street Capital Markets, LLC acted as co-placement agent.

The Private Placement will consist of 2,467,724 shares of common stock, or the Common Shares, at a price of $10.50 per share, 3,198.9419 shares of Series B-1 Convertible Preferred Stock, or the Series B-1 Shares, at a price of $10,500 per share, and 523.8094 shares of Series B-2 Convertible Preferred Stock, or the Series B-2 Shares, at a price of $10,500 per share, for aggregate gross proceeds of approximately $65.0 million, and net proceeds to the Company of approximately $60.0 million, after deducting estimated offering expenses payable by the Company. The closing of the Private Placement is expected to take place on or about March 4, 2020, and is subject to customary closing conditions. The Series B-1 Shares and Series B-2 Shares are collectively referred to herein as the Preferred Shares.

https://www.sec.gov/Archives/edgar/data/1651944/000119312520057797/d873792d8k.htm


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences